• Chemomab agreed to merge with Scipher Medicine in a stock transaction, creating a combined company expected to operate as Scipher Medicine.
• The combined company is expected to trade on Nasdaq under the ticker “SCIP” following completion.
• Deal values the combined company at $150 million before a concurrent $30 million private placement from a syndicate of investors.
• Strategy centers on advancing nebokitug, an anti-CCL24 antibody, into an AI-enabled Phase 2 rheumatoid arthritis trial using PrismRA-guided enrollment.
• Cash at closing is expected to fund operations into H2 2028; Phase 2 rheumatoid arthritis topline results are targeted for H1 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chemomab Therapeutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178913-26-003442), on July 08, 2026, and is solely responsible for the information contained therein.